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In this issue of Environmental Health Perspectives (EHP), Schecter et al. 
(2011) report levels of poly  brominated diphenyl ether (PBDE) flame 
retardants in butter purchased from retail stores. Although the investi-
gators found prevalent levels of PBDEs in butter, they report that one 
sample had inordinately high levels of octa-, nona-, and deca-BDE con-
geners, likely from its highly contaminated wrapping paper.
The safety of PBDEs has come into question (DiGangi et al. 2010). 
Chemical companies have voluntarily phased out penta- and octa-BDEs 
in the United States and have agreed to do so for deca-BDE production, 
and some states have banned PBDE use in consumer products such as 
mattresses and electronics (U.S. Environmental Protection Agency 2007, 
2010). The presence of these chemicals in food products has not been 
addressed explicitly in legislation or regulations in the United States.
Given the lack of clear regulatory guidance and the question of 
risk from high levels of PBDEs in food products, it is legitimate to 
ask:  should investigators in these types of “product biomonitoring” 
studies, when confronted with startling results from any potentially risky 
chemical, report their results to the manufacturer or to any regulatory 
agency prior to publication? Should the investigators identify specific 
brand name products and their manufacturers in their manuscript? More 
important, would the public want to know such results?
In a study of clinical trial subjects in brain imaging studies, Kirschen 
et al. (2006) found that at least 91% of the subjects, depending on the 
setting, wanted incidental findings to be disclosed to them, regard-
less of their clinical significance. In a workshop at which investigators 
discussed incidental findings, Illes (2006) found that most of the par-
ticipants believed that research protocols should provide for dis  closure of 
incidental findings. In environmental exposure studies there is no clear 
consensus on reporting individual data (Morello-Frosch et al. 2009), 
but Brody et al. (2007) found that an over  whelming majority of subjects 
(97%) were interested in knowing their personal results, regardless of the 
limited or absence of scientific information related to the health risks of 
that data.  
But the study by Schecter et al. (2011) is not a clinical trial, nor 
does the study include human subjects with measure  ments of internal 
exposures. On the other hand, the butter obtained for this study would 
otherwise have been purchased and consumed; additional lots of butter, 
similarly contaminated, may be awaiting purchase or may have already 
been consumed. In cases such as this, do clinical trial and environmen-
tal exposure reporting recommendations apply, including any ethical 
requirements to notify subjects of incidental findings? And who are the 
“subjects” in such product biomonitoring studies?
A secondary question relates to the planning of such research: Should 
product biomonitoring protocols plan for reporting of results? Should 
this issue be addressed in a pre  study protocol, perhaps subject to vetting 
by an institutional review board (IRB)–like committee with data safety 
monitoring board (DSMB) oversight? Clearly, product bio  monitoring 
studies without human subjects fall outside the realm of current IRB 
and DSMB jurisdiction. Given that IRBs and DSMBs are assembled 
to determine the risks to study participants, product contaminants 
of questionable risk may be too ambiguous for clear direction. These 
oversight bodies may thus be placed in a difficult position of interpret-
ing the science behind a particular contaminant in addition to advising 
the conduct of a research study. Regardless, it would be appropriate 
for investigators who conduct such studies to explicitly identify in their 
protocol procedures for handling and reporting results, both expected 
and unexpected. This may have implications on where and how data 
will be submitted for publication and use, but will likely help guide 
the investigators when surprising, incidental 
findings arise. Hernick et al. (2011) recently 
described their experience communicating   
unexpected biomarker results in a population 
of girls; their model may provide guidance for future research endeavors.
Some people may fear that making product biomonitoring data pub-
lic might generate alarm or panic among consumers, but research indi-
cates this is unlikely (Altman et al. 2008). Schecter’s research team has 
already published data on PBDEs in composite food samples (Schecter 
et al. 2010a) and on bisphenol A in identified, brand-name food prod-
ucts (Schecter et al. 2010b) without apparent widespread panic among 
the public. In addition, the Food and Drug Administration (FDA) con-
ducts regular market basket studies as part of its Total Diet Study (TDS) 
(FDA 2010). The TDS does not measure PBDEs (FDA 2009a), but it 
does measure other chemicals of concern in common consumer food 
products; results are made public (FDA 2009b), but the FDA does not 
identify specific brand names of sampled products or their manufacturers 
in their public data reports. The FDA does, however, pursue regulatory 
action if warranted by TDS results (Egan 2002).
Given the preferences of subjects in environmental exposure studies 
and the practice of the FDA in the TDS, it is clearly reasonable to make 
results of product biomonitoring studies public. But should a specific 
brand-name product or manufacturer be identified? One consideration 
is whether the product sampled in a study is representative of the totality 
of that product, or merely a small, inadvertently contaminated produc-
tion lot. It would be unfair for a single sample to tarnish the reputation 
of a product without additional data. In addition, the specter of litigation 
looms over such decisions (Ledford 2008). Reporting of results tied to 
a specific product or manufacturer may result in an injunction against 
publication, accompanied by a subpoena for original data or litigation to 
repeat studies for validation purposes prior to release of results. The jour-
nal publishing the paper may also find itself a party to such litigation. 
Schecter et al. (2011) indicate that they informed the butter manu-
facturer of their results. This was clearly a responsible act on their part. 
Making results public by publishing this important information in an 
open access journal such as EHP is also appropriate. Product manufac-
turers should act, of course, in the best interest of the public’s health. The 
issue of results notification in product bio  monitoring studies is worthy of 
more detailed examination, and consensus among researchers and jour-
nals should be a priority. 
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Editor’s Note
2010 Reviewers of the Year 
Like all peer-reviewed journals, EHP relies on the diligence and integ-
rity of experts to help determine the quality and impact of papers 
submitted for possible publication. In 2010 EHP received over 1,450 
papers, and about 550 of those papers were sent by our Associate 
Editors to at least two anonymous peer reviewers for evaluation. EHP 
published 268 papers in 12 issues during 2010, and the journal is very 
grateful for the time and effort of the more than 1,000 reviewers who 
assisted us last year. A list of those reviewers is available on the journal’s 
website (http://ehponline.org/article/info:doi/10.1289/ehp.119-a59). 
In this issue, EHP recognizes its top 12 Reviewers of the Year. These 
are individuals who reviewed at least five papers during the year and 
received excellent ratings for the timeliness and quality of their reviews 
by the Associate Editor who handled the peer-review process. They are 
Carol Angle, Adrian Barnett, Joe Braun, Jane Clougherty, Adrienne 
Ettinger, Matthew Longnecker, John Meeker, Sumi Mehta, David 
Savitz, Leonardo Trasande, Roberta White, and Judith Zelikoff. We 
congratulate these reviewers and thank the hundreds of others who 
contributed to the success of EHP in 2010.
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